

Ardea Biosciences, Inc./DE  
Form 3  
May 01, 2012

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

OMB  
Number: 3235-0104  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

ASTRAZENECA PLC  
(Last) (First) (Middle)

2 KINGDOM STREET  
(Street)

LONDON, W2 6BD  
(City) (State) (Zip)

2. Date of Event Requiring  
Statement

(Month/Day/Year)  
04/21/2012

3. Issuer Name and Ticker or Trading Symbol  
Ardea Biosciences, Inc./DE [RDEA]

4. Relationship of Reporting  
Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_X\_\_\_\_ 10% Owner  
\_\_\_\_ Officer \_\_\_\_ Other  
(give title below) (specify below)

5. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group  
Filing(Check Applicable Line)  
\_\_\_\_X\_\_\_\_ Form filed by One Reporting  
Person  
\_\_\_\_ Form filed by More than One  
Reporting Person

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security  
(Instr. 4)

Common Stock

2. Amount of Securities  
Beneficially Owned  
(Instr. 4)

0 (1) (2) (3) (4) (5) (6)

3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)

I (1) (2) (3)  
(4) (5) (6)

4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

See Footnotes (1) (2) (3) (4) (5) (6)

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)  
Title

4. Conversion  
or Exercise  
Price of  
Derivative  
Security

5. Ownership  
Form of  
Derivative  
Security:  
Direct (D)

6. Nature of Indirect  
Beneficial Ownership  
(Instr. 5)

Date Exercisable	Expiration Date	Amount or Number of Shares	or Indirect (I) (Instr. 5)
---------------------	--------------------	----------------------------------	----------------------------------

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ASTRAZENECA PLC 2 KINGDOM STREET LONDON, X0 W2 6BD	Â	Â X	Â	Â

## Signatures

Adrian Kemp, Secretary, on behalf of  
AstraZeneca PLC

05/01/2012

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This form is a joint filing by (i) Zeneca Inc. ("Zeneca"); (ii) Zeneca Holdings Inc.; (iii) AstraZeneca Holdings BV; (iv) AstraZeneca Treasury Limited; (v) AstraZeneca UK Limited; (vi) AstraZeneca Intermediate Holdings Limited; and (vii) AstraZeneca PLC (all entities listed in (i) through (vii), the "AZ Entities"). AstraZeneca PLC is the direct parent of AstraZeneca Intermediate Holdings Limited and the indirect parent of the entities listed in (i) through (v). The address of each of the AZ Entities is listed in Exhibit 99.1.

(2) As an inducement to Zeneca entering into the Agreement and Plan of Merger, dated as of April 21, 2012 (the "Merger Agreement"), by and among Zeneca, QAM Corp. and Ardea Biosciences, Inc. ("Ardea"), and in consideration thereof, Zeneca and certain directors and executive officers of Ardea and certain of their respective affiliates (the "Key Stockholders") entered into Voting Agreements, dated as of April 21, 2012 (the "Voting Agreements"), (continued in Footnote 3)

(3) pursuant to which the Key Stockholders have agreed to vote, or cause to be voted, all shares of Ardea common stock ("Shares") beneficially owned by them (i) in favor of the adoption of the Merger Agreement and, without limitation of the preceding language, the approval of certain proposals to adjourn or postpone any meeting of Ardea stockholders to a later date if there are not sufficient votes for adoption of the Merger Agreement on the date on which such meeting is held, and (ii) against (a) any proposal made in opposition to, or in competition with, the transactions contemplated by the Merger Agreement and (b) any acquisition transaction and any other action or agreement that is intended to or would reasonably be expected to impede, prevent, delay or adversely affect the transactions contemplated by the Merger Agreement, in each case, on the terms and subject to the conditions set forth in the Voting Agreements.

(4) The AZ Entities, by reason of the execution and delivery by Zeneca of the Voting Agreements, may be deemed to have shared voting power with the Key Stockholders with respect to (and therefore beneficially own within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act")) an aggregate of 10,886,949 Shares (representing approximately 29.6% of Ardea's issued and outstanding Shares (assuming 36,768,915 Shares issued and outstanding as of April 18, 2012, as represented by Ardea in the Merger Agreement)) and shared dispositive power with the Key Stockholders with respect to an aggregate of 12,181,075 Shares (comprised of (i) 10,886,949 issued and outstanding Shares and (ii) 1,294,126 Shares issuable upon exercise of outstanding options and warrants that are subject to the Voting Agreements.

(5) None of the AZ Entities have any pecuniary interest in the Shares and therefore do not have beneficial ownership of any Shares within the meaning of Rule 16a-1(a)(2) of the Exchange Act.

(6) Neither the filing of this Form 3 nor any of its contents shall be deemed to constitute an admission by any AZ Entity or any other person that he, she or it is the beneficial owner of any of the Shares referred to herein for purposes of Section 13(d) or Section 16 of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.

Â

### Remarks:

Exhibits:Â 99.1 NameÂ andÂ addressÂ ofÂ eachÂ ofÂ theÂ AZÂ Entities;Â 99.2  
SignatureÂ ofÂ eachÂ AZÂ EntityÂ (otherÂ thanÂ AstraZenecaÂ PLC)

## Edgar Filing: Ardea Biosciences, Inc./DE - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.